	US 12,358,911 B2
	Heterocyclic comipound as CDK-HDAC dual pathway inhibitor
Hancheng Zhang, Zhejiang (CN); Xiangyang Ye, Zhejiang (CN); and Xin Cheng, Zhejiang (CN)
Assigned to Hangzhou Innogate Pharma Co., Ltd., Zhejiang (CN)
Appl. No. 17/311,627
Filed by Hangzhou Innogate Pharma Co., Ltd., Zhejiang (CN)
PCT Filed Dec. 9, 2019, PCT No. PCT/CN2019/124143 § 371(c)(1), (2) Date Jun. 7, 2021, PCT Pub. No. WO2020/114519, PCT Pub. Date Nov. 6, 2020.
Claims priority of application No. 201811497798.X (CN), filed on Dec. 7, 2018.
Prior Publication US 2022/0024916 A1, Jan. 27, 2022
Int. Cl. C07D 471/04 (2006.01); A61P 35/00 (2006.01)

CPC C07D 471/04 (2013.01) [A61P 35/00 (2018.01)]

4 Claims

1. A compound selected from the group consisting of: